CAR-T In Vitro Efficacy Services with OncoSolid™ Head and Neck Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Head and Neck Cancer Organoid Models

Head and neck cancer is a collective name of cancers that take place in the mucosal epithelium of the oral cavity, nasopharynx, hypopharynx, oropharynx, and larynx. Head and neck squamous cell carcinoma (HNSCC) is a common type of malignant that shows poor outcomes to classical treatment. Cancer organoids, especially patient-derived organoids (PDO), recapitulate the key features of human tumor tissue and are reliable models for evaluating tumor responses in patients. Creative Biolabs offers well-characterized head and neck organoid lines from multiple anatomical locations and cancer subtypes with defined antigen protein expression for tumor immunotherapy efficacy tests.

Key Features of Our Cancer Organoid Models-based CAR-T Anti-tumor Efficacy Evaluation Services

Patients-derived organoids maintain the HPV infection status of primary tissues. Cancer-associated fibroblast can be added to the culture system to improve organoid formation ability. The establishment rate is about 30% but increased to 80% when epithelial cells are included. Our culture system is optimized to produce more organoid numbers with bigger sizes.

Multiple Head and Neck Cancer Organoid Lines Available

Diverse Head and Neck Cancer Organoids
Squamous cell carcinoma (SCC) Adenocarcinoma (AC) Large cell carcinoma (LCC) Mucoepidermoid (MucoEC) Adenoid cystic carcinoma (AdCC) Myoepithelial carcinoma (MyoEC)

Characterization of Head and Neck Cancer Organoids

We test the relevance of patient-derived organoids compared to original tumor tissue from cellular and molecular aspects.

Fig.1 Established cancer organoids profiling. (Creative Biolabs)

Cell Markers for Head and Neck Cancer Organoids Identification

Cell	Biomarker	Cell	Biomarker	Cell	Biomarker
Epithelial cell	AE1AE3, Pankeratin	Differentiated squamous cell	Cytokeratin 13	Basal cell	p63
Cancer stem cell	ALDH1A1 and CD44	Mesenchymal cell	Vimentin	Macrophage and Langerhans cells	CD68

Our Head and Neck Cancer Related CAR-T Products and Services

With years of deep study on cell therapy, Creative Biolabs masters the prevailing immune cell engineering technologies and offers CAR cells related products for researchers to test engineered cell functions in vitro, such as cancer organoids mediated cytotoxicity tests.

Target antigen	Target description	CAR-T Products
ErbB	Pan-ErbB represents the ErbB family that contains four epidermal growth factor receptors named ErbB-1, ErbB-2 (HER2/neu), ErbB-3, and ErbB-4. Pan-ErbB has become an attractive biomarker for targeted therapies.	Anti-ErbB CAR-T
HER2	HER2 also named as ErbB2, HER2, or c-erbB2. High levels of HER2 expression in squamous cell carcinoma are related to poor survival and an increased rate of recurrence.	Anti-HER2 CAR-T
EGFR	Human epidermal growth factor receptor (EGFR), also called ErbB-1 or HER1, is an oncogenic gene with high expression in lung cancer and head and neck tumors, serving as a target for CAR-T therapy.	Anti-EGFR CAR-T

Case Study

Published Data I

Head and Neck Organoids Show Similar Phenotypical Characteristics as Parent Tumor
Fig.2 Organoids are tested for histological structure. (Tanaka, et al., 2018)
Fig.3 Organoids and original tumors are tested for specific cell populations using IHC staining. (Tanaka, et al., 2018)

Published Data II

HNSCC Organoid Lines Are Established to Test EGFR Targeted Therapies
Highlights: Patient-derived cancer organoids retain the EGFR expression levels of individual donor tumor tissue. Cancer/normal organoids are treated with anti-EGFR antibody-mediated photodynamic therapy (PDT), and the response to treatment is correlated to EGFR expression level in organoids. Organoids can be engineered to overexpress EGFR by lentivirus.
Fig.4 Organoids recapitulate EGFR expression in parental tumor specimen. (Driehuis, et al., 2019)
Fig.5 The response of Cancer organoids to antibody-based PDT therapy is detected by cell viability alteration. (Driehuis, et al., 2019)

Creative Biolabs offers faster development and enhanced cultures of organoids for CAR-T anti-tumor activity evaluation. please contact us and get more detailed information.

References

Driehuis, E.; et al. Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. Journal of clinical medicine. 2019, 8(11): 1880.
Tanaka, N.; et al. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral oncology. 2018, 87: 49-57.